Chinook: Surprising Acquisition By Novartis, Deal Should Go Through
Summary
- Novartis has struck a deal to acquire Chinook Therapeutics for $3.5 billion in cash, with Chinook shareholders set to gain $40 per share and a potential additional $300 million if regulatory hurdles are cleared.
- By buying Chinook, Novartis will be able to enter into one of the hottest rare disease spaces with attractive pricing power.
- Despite risks such as regulatory concerns (FTC blocking the deal), we believe there is a high likelihood that the deal goes through.
Sewcream
Key update: The best outcome for investors
On June 12th, Novartis (NVS) announced that the company has struck a deal to acquire Chinook Therapeutics (NASDAQ:KDNY) for $3.5Bn in cash. As soon as the news was published, Chinook's stocks gained 67%+ and is currently trading around $37.9.
According to the press announcement:
Chinook shareholders stand to gain $3.2 billion, equivalent to $40 per share in cash, once the deal is closed, in addition to a contingent value right potentially worth ~$300mn if regulatory hurdles go through.
We believe the decision was based on Novartis's effort to acquire late-stage pipeline candidates targeting two distinct mechanisms of action, a) ERA (atrasentan) targeting more early stage, and b) anti-APRIL, targeting late stage. Through acquiring Chinook, we believe Novartis will be able to leverage a pre-existing established rare disease and kidney commercial force to market those two products.
We believe that for investors who hold shares on Chinook, this was the best possible outcome considering that a) overhang around eGFR that we have seen from Travere's (TVTX) sparsentan (that did not meet statistically significant eGFR improvement during its FSGS trial) still haunts Atrasentan (if during the ALIGN trial Atrasentan doesn't show statistical significant eGFR, the FDA will likely not allow the drug to be approved through an accelerated pathway), b) the deal was at a significant premium, where we were hoping the stock to trend toward after the positive IgAN data, and c) the risk of the deal falling through (biggest risk for a merger arbitrage trade) is limited considering Novartis is a major big pharma player with deep pockets.
We expect the deal to go through
Moving forward, we believe the key question to consider is whether the FTC will allow the deals to go through. The short answer is that we do not think the FTC will have an issue with the deal due to three reasons, a) IgAN space is crowded with multiple candidates competing, even within the ERA and APRIL inhibitor space (chart below), b) Chinook is a Canadian company (Vancouver based) and would have lesser geopolitical considerations to be made (vs US biotech), and c) Chinook is a small/mid-cap biotech without cashflow (it would be a different story for two large-cap pharmas dominating the kidney space to merge with each other).
IgAN space has become highly congested with multiple players:
Drug Company Description Status Reduction in proteinuria Tarpeyo Calliditas Oral formulation of budesonide Approved (accelerated); eGFR data reported Mar 2023 34% (31% pbo-adjusted) in ph3 Nefigard Filspari (sparsentan) Travere Oral endothelin type A & angiotensin II type 1 inhibitor Approved (accelerated); eGFR data due Q4 2023 50% (35 points adjusted for irbesartan control) in ph3 Protect Narsoplimab (OMS721) Omeros Anti-MASP2 antibody Ph3 Artemis-IgAN; proteinuria data due mid-2023 64% (no control arm) in ph2 Atrasentan Chinook Oral endothelin A receptor inhibitor Ph3 Align; proteinuria data due H2 2023 55% (no control arm) in ph2 Affinity Iptacopan (LNP023) Novartis Oral complement factor B inhibitor Ph3 Applause-IgAN; proteinuria data due H2 2023 23% pbo-adjusted in ph2* Sibeprenlimab (VIS649) Otsuka Anti-April antibody Ph3 Visionary ends Dec 2026 43% pbo-adjusted in ph2** *At highest dose (200mg BID); **pooled data with IV doses 2mg, 4mg & 8mg monthly. Source: Evaluate Pharma & clinicaltrials.gov. Source: Evaluate Pharma
Risks
Regulatory Risk: Even though we believe the deal will go through, there is always a risk that regulatory bodies, such as the Federal Trade Commission, could block or delay the merger. This could happen if there are concerns about creating a monopoly or other anticompetitive behavior, which can impact the share price and expected deal completion.
Drug Development and Approval Risk: Chinook's pipeline drugs, like atrasentan, are still in the trial phase and there is a risk that they might not meet their clinical endpoints or fail to gain regulatory approval. Even slight negative news about the drug's efficacy or safety could influence Chinook's share price negatively.
Market Competition: The IgA nephropathy (IgAN) space is becoming highly crowded. There are multiple companies, each with their candidates in various stages of development. This intense competition can pose a risk to the future commercial prospects of Chinook's pipeline, which can influence its valuation and Novartis may potentially decide to walk away from the deal.
Geopolitical Risks: While Chinook is a Canadian company, and might not face intense scrutiny as a U.S. company would, geopolitical risks can still affect the merger. Unexpected changes in trade policies, political unrest, or a shift in international relations could potentially delay or disrupt the deal process.
Financial Risks: If, for any reason, Novartis experiences financial difficulties or changes its strategic priorities, they might reconsider the acquisition, causing significant risk to Chinook's shareholders who are counting on the premium from the sale.
Conclusion
In a major development, Swiss pharmaceutical giant Novartis is set to acquire Chinook Therapeutics for a cash deal of $3.5 billion, causing Chinook's stock to surge by over 67%. Despite the inherent risks involved in such mergers, including regulatory concerns, we believe this deal is poised to go through without a problem. Given Novartis' reputation and Chinook's Canadian origins and status as small/mid-cap biotech, it's unlikely that the Federal Trade Commission would block the deal. We maintain a buy rating on Chinook until the deal closes.
This article was written by
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Biotechvalley Insights (BTVI) is not a registered investment advisor, and articles are not targeted toward retail investors. The content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in our articles or comments constitutes a solicitation, recommendation, endorsement, or offer by Biotechvalley Insights or any third-party service provider to buy or sell any securities or other financial instruments in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. The research and reports made available by BTVI reflect and express the opinion of the applicable BTVI entity as of the time of the report only. Reports are based on generally-available information, field research, inferences, and deductions through the applicable due diligence and analytical process. BTVI may use resources from brokerage reports, corporate IR, and KOL/expert interviews that may have a conflict of interest with the company/assets that BTVI covers. To the best of the applicable BTVI's ability and belief, all information contained herein is accurate and reliable, is not material non-public information, and has been obtained from public sources that the applicable BTVI entity believes to be accurate and reliable. However, such information is presented “as is” without warranty of any kind, whether express or implied. With respect to their respective research reports, BTVI makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information or with regard to the results to be obtained from its use. Further, any analysis/comment contains a very large measure of analysis and opinion. All expressions of opinion are subject to change without notice, and BTVI does not undertake to update or supplement any reports or any of the information, analysis, and opinion contained in them.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.